Slate Path Capital LP Arrowhead Pharmaceuticals, Inc. Transaction History
Slate Path Capital LP
- $6.33 Billion
- Q3 2024
A detailed history of Slate Path Capital LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Slate Path Capital LP holds 4,885,000 shares of ARWR stock, worth $95.4 Million. This represents 1.49% of its overall portfolio holdings.
Number of Shares
4,885,000
Previous 4,139,000
18.02%
Holding current value
$95.4 Million
Previous $108 Million
12.08%
% of portfolio
1.49%
Previous 2.11%
Shares
3 transactions
Others Institutions Holding ARWR
# of Institutions
294Shares Held
90.8MCall Options Held
155KPut Options Held
426K-
Black Rock Inc. New York, NY15.7MShares$306 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$239 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$174 Million2.59% of portfolio
-
State Street Corp Boston, MA6.35MShares$124 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.57MShares$69.8 Million0.04% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.07B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...